Evidence map›Paper›PMID 33163723›Full record

ArticleKidney international reports2020

Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity.

Anatilde M Gonzalez Guerrico, John Lieske, George Klee, Sanjay Kumar, Victor Lopez-Baez, Adam M Wright, Shane Bobart, Diane Shevell, Michael Maldonado, Jonathan P Troost and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Biomarkers in pediatric glomerulonephritis and nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Anatilde M Gonzalez GuerricoDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
John LieskeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
George KleeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Sanjay KumarDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Victor Lopez-BaezDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Adam M WrightDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Shane BobartDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Diane ShevellBristol-Myers Squibb, Lawrenceville, New Jersey, USA.
Michael MaldonadoBristol-Myers Squibb, Lawrenceville, New Jersey, USA.
Jonathan P TroostMichigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, Michigan, USA.
Marie C HoganDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Nephrotic Syndrome Study Network Consortium (NEPTUNE)
Mayo Clinic · USBristol-Myers Squibb (United States) · USUniversity of Michigan–Ann Arbor · US

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Training Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GIPSON, DEBBIE S · 2009 to 2023
$20.3M
NCATS NIH HHS UL1 TR002240NCATS NIH HHS UL1 TR002548NIDDK NIH HHS U54 DK083912
6 · The paper itself

Abstract

introductionHeterogeneity of nephrotic diseases and a lack of validated biomarkers limits interventions and reduces the ability to examine outcomes. Urinary CD80 is a potential biomarker for minimal change disease (MCD) steroid-sensitive nephrotic syndrome (NS). We investigated and validated a CD80 enzyme-linked immunosorbent assay (ELISA) in urine in a large cohort with a variety of nephrotic diseases.

methodsA commercial CD80 ELISA was enhanced and analytically validated for urine. Patients were from Mayo Clinic (307) and Nephrotic Syndrome Study Network Consortium (NEPTUNE; 104) as follows: minimal change disease (MCD, 56), focal segmental glomerulosclerosis (FSGS, 92), lupus nephritis (LN, 25), IgA nephropathy (IgAN, 20), membranous nephropathy (MN, 49), autosomal dominant polycystic kidney disease (ADPKD, 10), diabetic nephropathy (DN; 106), pyuria (19), and controls (34). Analysis was by Kruskal-Wallis test, generalized estimating equation (GEE) models, and receiver operating characteristic (AUC) curve.

resultsUrinary CD80/creatinine values were highest in MCD compared to other glomerular diseases and were increased in DN with proteinuria >2 compared to controls (control = 36 ng/g; MCD = 139 ng/g,

conclusionUsing a validated ELISA, urinary CD80 levels discriminate MCD from other forms of NS (FSGS, DN, IgA, MN) and primary from secondary FSGS.

Indexed as

CD80focal segmental glomerulosclerosislupus nephritisminimial change diseasenephrotic syndrome

Identifiers

PMID33163723
PMCPMC7609973
OpenAlexW3049147108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.